0001104659-21-005571.txt : 20210119
0001104659-21-005571.hdr.sgml : 20210119
20210119215340
ACCESSION NUMBER: 0001104659-21-005571
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210114
FILED AS OF DATE: 20210119
DATE AS OF CHANGE: 20210119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Astley-Sparke Philip
CENTRAL INDEX KEY: 0001376491
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38596
FILM NUMBER: 21537309
MAIL ADDRESS:
STREET 1: C/O BIOVEX GROUP, INC.
STREET 2: 34 COMMERCE WAY
CITY: WOBURN
STATE: MA
ZIP: 10801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Replimune Group, Inc.
CENTRAL INDEX KEY: 0001737953
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 822082553
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
BUSINESS PHONE: (781) 222-9600
MAIL ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
4
1
tm213368-6_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-01-14
0
0001737953
Replimune Group, Inc.
REPL
0001376491
Astley-Sparke Philip
C/O REPLIMUNE GROUP, INC.
500 UNICORN PARK
WOBURN
MA
01801
1
1
0
0
Chief Executive Officer
Common Stock
2021-01-14
4
S
0
17452
44.78
D
1287845
D
Common Stock
2021-01-14
4
S
0
7448
43.61
D
1280397
D
Common Stock
2021-01-14
4
S
0
100
43.06
D
1280297
D
Common Stock
2021-01-15
4
S
0
1100
44.95
D
1279197
D
Common Stock
2021-01-15
4
S
0
6059
43.71
D
1273138
D
Common Stock
2021-01-15
4
S
0
9409
43.02
D
1263729
D
Common Stock
2021-01-19
4
S
0
800
43.15
D
1262929
D
Common Stock
2021-01-19
4
S
0
7632
42.40
D
1255297
D
The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.09 to $45.08. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.14 to $44.07. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.55 to $45.26. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.26 to $44.25. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.56 to $43.25. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.86. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.04 to $42.85. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,255,297 shares of the Issuer's common stock. The reporting person also holds options to acquire 647,571 shares of the Issuer's common stock, 230,907 of which are exercisable as of the date hereof.
/s/ Jean Franchi, attorney-in-fact
2021-01-19